Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STX400
- Development stage
- Preclinical
- Lead developer
- SyntheX
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01
Overview
STX400 is a paralog-specific targeted protein degrader developed by SyntheX Labs (also known as Digitoid Synthex) for the treatment of NRas-driven cancers. Utilizing the company's proprietary ToRNeDO platform technology for target-centric cell-based functional selection, STX400 is a small molecule engineered to selectively induce the degradation of the NRas protein while sparing other RAS family members, such as KRAS and HRAS. This selectivity is designed to address oncogene addiction in cancers specifically driven by NRas mutations while minimizing potential toxicities associated with pan-RAS inhibition. The program is currently in the preclinical development phase and is part of SyntheX's oncology-focused pipeline targeting the RAS/MAPK pathway.
- Other names
- NRas degraderNRas paralog-specific degraderNRas targeted protein degrader
02
Targets
NRAS (NRAS proto-oncogene GTPase)
Beyond the preview
Go deeper on STX400.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STX400.